In Vitro: KRFK (50 μM; 24 h) activates the secretion of TGF-β and reduces the expression of DC maturation markers in tsp-1 deficient bone marrow-derived dendritic cells (BMDCs) .
In Vivo: KRFK (5 μg/5 μL/eyes; single dose) significantly prevents the development of chronic ocular surface inflammation in TSP-1-/- mice.